Sign in
SMMT Stock Price, Chart, Stats & News
Summit Therapeutics Inc.
Save
11.06B
Market cap
–
Current P/E
3.72x
Forward P/E
SMMT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -143.72% |
ROE | -296.82% |
D/E | 0.02x |
Interest coverage ratio | – |
SMMT valuation
P/E | – |
P/S | – |
P/B | 18.82x |
P/CF | -38.39x |
P/FCF | -38.14x |
P/OCF | -38.39x |
PEG | 0.68x |
EV multiple | -15.67x |
About
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI.
Similar securities
Based on sector and market capitalization
Report issue